Description: NovoCure Limited develops and commercializes treatment for solid tumor cancers therapy called the tumor treating fields (TTFields). The company markets its proprietary therapy, TTFields delivery system under the Optune name for use as a monotherapy treatment for adult patients with glioblastoma brain cancer. NovoCure Limited also conducts clinical trials for the use of TTFields in brain metastases, advanced non-small cell lung cancer, pancreatic cancer, ovarian cancer, and mesothelioma. The company markets its products in the United States, as well as in European Union member states, Switzerland, and Japan. NovoCure Limited was founded in 2000 and is based in Saint Helier, Channel Islands.
Home Page: www.novocure.com
NVCR Technical Analysis
No. 4 The Forum
Saint Helier,
JE2 4UF
Jersey
Phone:
44 15 3475 6700
Officers
| Name | Title |
|---|---|
| Mr. William F. Doyle | Exec. Chairman |
| Mr. Asaf Danziger | Pres, CEO & Director |
| Ms. Ashley Cordova | Chief Financial Officer |
| Mr. Wilhelmus C. M. Groenhuysen | Chief Operating Officer |
| Mr. Pritesh Shah | Chief Commercial Officer |
| Prof. Yoram Palti M.D., Ph.D. | Founder & CTO |
| Mr. Uri Weinberg M.D., Ph.D. | Chief Science Officer |
| Ms. Ingrid Goldberg | VP of Investor Relations |
| Mr. Barak Ben Arye | Gen. Counsel |
| Mr. William Patrick Burke | Chief HR Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Health Care Equipment & Services |
| GIC Industry: | Health Care Equipment & Supplies |
| GIC Sub-Industry: | Health Care Equipment |
| Forward PE: | 909.0909 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 17.9456 |
| Price-to-Sales TTM: | 14.357 |
| IPO Date: | 2015-10-02 |
| Fiscal Year End: | December |
| Full Time Employees: | 1167 |